Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
- Market Cap ₹ 43,144 Cr.
- Current Price ₹ 1,529
- High / Low ₹ 1,831 / 767
- Stock P/E
- Book Value ₹ 299
- Dividend Yield 0.16 %
- ROCE 12.3 %
- ROE -50.9 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Debtor days have improved from 88.3 to 57.4 days.
- Company's working capital requirements have reduced from 96.9 days to 31.8 days
Cons
- Stock is trading at 5.11 times its book value
- The company has delivered a poor sales growth of 3.67% over past five years.
- Company has a low return on equity of -10.6% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Total Market BSE 250 SmallCap Index Nifty MidSmallcap 400 Nifty 500 Multicap 50:25:25 BSE MidCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5,012 | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 12,248 | |
3,997 | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 9,948 | 10,618 | 10,762 | |
Operating Profit | 1,015 | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 1,635 | 1,195 | 1,486 |
OPM % | 20% | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 14% | 10% | 12% |
11 | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -10 | 336 | 509 | |
Interest | 160 | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 349 | 516 | 371 |
Depreciation | 127 | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 569 | 582 | 536 |
Profit before tax | 739 | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 707 | 434 | 1,087 |
Tax % | 15% | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 47% | 430% | |
628 | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | -850 | |
EPS in Rs | 22.89 | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | -31.01 |
Dividend Payout % | 0% | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 4% |
3 Years: | 3% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -454% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 35% |
3 Years: | 42% |
1 Year: | 89% |
Return on Equity | |
---|---|
10 Years: | 5% |
5 Years: | -3% |
3 Years: | -11% |
Last Year: | -51% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 27 | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
Reserves | 2,736 | 2,956 | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,417 |
2,765 | 3,267 | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,608 | 1,231 | 1,711 | |
1,466 | 2,176 | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,289 | 5,279 | 5,009 | |
Total Liabilities | 6,994 | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,165 |
2,822 | 3,091 | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 | 4,507 | |
CWIP | 6 | 5 | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,190 | 662 | 395 |
Investments | 0 | 0 | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 45 |
4,166 | 5,331 | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 12,715 | 8,697 | 10,219 | |
Total Assets | 6,994 | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,165 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
648 | 854 | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 | |
-558 | -566 | -712 | -950 | -1,001 | -1,003 | -883 | -774 | -662 | -316 | -515 | 4,387 | |
195 | -98 | 199 | 699 | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3,906 | |
Net Cash Flow | 285 | 190 | -31 | 93 | 199 | 177 | -297 | 174 | 28 | 272 | 32 | 215 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 119 | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 |
Inventory Days | 194 | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 |
Days Payable | 239 | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 |
Cash Conversion Cycle | 75 | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 |
Working Capital Days | 94 | 83 | 66 | 89 | 133 | 111 | 76 | 69 | 96 | 100 | 159 | 32 |
ROCE % | 18% | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - IGI presents promising Phase 1 data for ISB 2001.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 27 Nov
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
27 Nov - Glenmark launches Travoprost Ophthalmic Solution USP, 0.004%.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
21 Nov - Transcript of earnings call held on Monday, November 18, 2024 for the second quarter ended September 30, 2024 has been uploaded on Company''s website.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
18 Nov - Uploaded audio recording of Q2 FY 2024-25 earnings call.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Dec 2016TranscriptNotesPPT
-
Jul 2016TranscriptNotesPPT
-
Jan 2016TranscriptNotesPPT
Leadership[1]
<h1>14th largest and fastest growing in the Indian market</h1> <h1>15th largest generic company by prescriptions filled in the USA</h1> <h1>5th largest Indian generic co. in Europe.</h1>